ZUG, Switzerland, Sept. 20, 2017 -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that Thomas Meyer, Ph.D., Chairman and Chief Executive Officer, will present at the LEERINK Partners Rare Disease Roundtable Series in New York City on Wednesday, September 27, 2017, at 9:30 a.m. Eastern Time. A live webcast of the event will be available through the Events and Presentations page in the Investors section of the Auris Medical website at www.aurismedical.com, and a replay of the presentation will be available following the event.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in neurotology. The company is focused on the Phase 3 development of treatments for acute inner ear hearing loss (AM-111) and for acute inner ear tinnitus (Keyzilen®; AM-101) by way of intratympanic administration with biocompatible gel formulations. In addition, Auris Medical is developing intranasal betahistine for Meniere's disease and other vestibular disorders (AM-125) as well as early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS."
Contact: Cindy McGee, Head of Investor Relations and Corporate Communications, +41 61 201 1350, [email protected]
Media contact: David Schull, Russo Partners, 1-858-717-2310,
[email protected]


JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Italy Fines Apple €98.6 Million Over App Store Dominance
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
FDA Approves Mitapivat for Anemia in Thalassemia Patients
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 



